1.1.1. Depression: EPDS – Sensitivity and Specificity

EPDS-Pregnancy – Mixed depression – 9/10 cut-off

EPDS-Pregnancy-Mixed depression – 12/13 cut-off

EPDS-Pregnancy-Mixed depression – 14/15 cut-off

EPDS-Pregnancy – Major depression – 9/10 cut-off

EPDS-Pregnancy – Major depression – 12/13 cut-off

EPDS-Pregnancy – Major depression – 14/15 cut-off

EPDS-Postnatal – Mixed depression – 9/10 cut-off

EPDS-Postnatal-Mixed depression – 12/13 cut-off

EPDS-Postnatal-Major depression – 9/10 cut-off

EPDS-Postnatal-Major depression – 12/13 cut-off

1.1.2. Depression: PHQ – Sensitivity and Specificity

PHQ – All versions, timings and cut-offs

1.1.3. Depression – Whooley Questions: Sensitivity and Specificity

Whooley Questions – All versions, timings and cut-offs

1.1.4. Depression: Kessler-10 – Sensitivity and Specificity

Kessler-10 – PHQ – All versions, timings and cut-offs

1.1.5. Anxiety: EPDS – Sensitivity and Specificity

EPDS – All versions, timings and cut-offs

1.1.6. Anxiety: Kessler-10 – Sensitivity and Specificity

Kessler-10 - All versions, timings and cut-offs

1.2.1. Depression: Post-miscarriage self-help versus TAU

Depression mean symptoms Post-treatment – ITT analysis (at-risk populations)

1.2.2. Depression: Social support versus TAU

Depression diagnosis Post-treatment – ITT analysis (at-risk populations)

Depression diagnosis Post-treatment – Available case analysis (at-risk populations)

1.2.3. Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Depression diagnosis Post-treatment – ITT analysis (at-risk populations)

Depression diagnosis Post-treatment – Available case analysis (at-risk populations)

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment – Available case analysis (at-risk populations)

Depression mean scores Post-treatment – Available case analysis (at-risk populations)

Depression diagnosis Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)

Depression diagnosis Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.4. Depression: Psychoeducational booklet versus TAU or Enhanced TAU

Depression symptomatology Post-treatment) – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment – Available case analysis (at-risk populations)

Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.5. Depression: Non-mental health-focused education and support versus TAU or Enhanced TAU

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment – Available case analysis (at-risk populations)

Depression mean scores Post-treatment – ITT analysis (at-risk populations)

Depression mean scores Post-treatment – Available case analysis (at-risk populations)

Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Long Follow-up (25-103 weeks post-intervention) -Available case analysis (at-risk populations)

1.2.6. Depression: Home visits versus TAU

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment – Available case analysis (at-risk populations)

Depression mean scores Post-treatment – Available case analysis (at-risk populations)

Depression symptomatology Very long Follow-up (>104 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Very long Follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Very long Follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.7. Depression: Post-delivery discussion versus Enhanced TAU

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment – Available case analysis (at-risk populations)

Depression mean scores Post-treatment – Available case analysis (at-risk populations)

Depression symptomatology Very long Follow-up (>104 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Very long Follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Very long Follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.8. Depression: Mother-infant relationship interventions versus TAU

Depression diagnosis Post-treatment – ITT analysis (at-risk populations)

Depression diagnosis Post-treatment – Available case analysis (at-risk populations)

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment – Available case analysis (at-risk populations)

Depression mean scores Post-treatment – Available case analysis (at-risk populations)

Depression mean scores Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Depression diagnosis Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Depression diagnosis Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Depression symptomatology Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Depression mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.9. Depression: Case management and individualised treatment versus TAU

Depression symptomatology Post-treatment – ITT analysis (at-risk populations)

Depression symptomatology Post-treatment -Available case analysis (at-risk populations)

1.2.10. Anxiety: Post-miscarriage self-help versus TAU

Anxiety mean scores Post-treatment – ITT analysis (at-risk populations)

1.2.11. Anxiety: Non-mental health-focused education and support versus TAU or Enhanced TAU

Anxiety symptomatology Post-treatment – ITT analysis (at-risk populations)

Anxiety symptomatology Post-treatment – Available case analysis (at-risk populations)

Anxiety mean scores Post-treatment – Available case analysis (at-risk populations)

Anxiety symptomatology Short Follow-up (9-16 weeks post-intervention) – ITT analysis (at-risk populations)

Anxiety symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Anxiety mean scores Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Anxiety symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)

Anxiety symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

Anxiety mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.12. Anxiety: Home visits versus TAU

Anxiety symptomatology Post-treatment – ITT analysis (at-risk populations)

Anxiety symptomatology Post-treatment – Available case analysis (at-risk populations)

Anxiety mean scores Post-treatment – Available case analysis (at-risk populations)

Anxiety symptomatology Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Anxiety symptomatology Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Anxiety mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.13. PTSD: Post-miscarriage self-help versus TAU

PTSD symptomatology Post-treatment – ITT analysis (at-risk populations)

PTSD mean scores Post-treatment – ITT analysis (at-risk populations)

1.2.14. General mental health: Post-miscarriage self-help versus TAU

General mental health mean scores Post-treatment – ITT analysis (at-risk populations)

1.2.15. General mental health: Home visits versus TAU

General mental health mean scores Post-treatment – Available case analysis (at-risk populations)

1.2.16. General mental health: Post-delivery discussion versus Enhanced TAU

General mental health mean scores Post-treatment – Available case analysis (at-risk populations)

General mental health mean scores Very long follow-up (>104 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.17. General mental health: Mother-infant relationship interventions versus TAU

General mental health mean scores Post-treatment – Available case analysis (at-risk populations)

General mental health mean scores Long follow-up (25-104 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.18. Mother-infant attachment: Non-mental health-focused education and support versus TAU or Enhanced TAU

Mother-infant attachment problems Post-treatment – ITT analysis (at-risk populations)

Mother-infant attachment problems Post-treatment – Available case analysis (at-risk populations)

Positive mother-infant interaction mean scores Post-treatment – Available case analysis (at-risk populations)

Maternal sensitivity mean scores Post-treatment – Available case analysis (at-risk populations)

Maternal confidence mean scores Post-treatment – Available case analysis (at-risk populations)

Mother-infant attachment problems Short Follow-up (9-16 weeks post-intervention) – ITT analysis (at-risk populations)

Mother-infant attachment problems Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Mother-infant attachment problems Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (at-risk populations)

Mother-infant attachment problems Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.19. Mother-infant attachment: Home visits versus TAU

Maternal sensitivity mean scores Post-treatment – Available case analysis (at-risk populations)

Infant involvement mean scores Post-treatment – Available case analysis (at-risk populations)

Discontinued breastfeeding <6 months – ITT analysis (at-risk populations)

1.2.20. Mother-infant attachment: Mother-infant relationship interventions versus TAU

Mother-infant attachment problems Post-treatment – ITT analysis (at-risk populations)

Mother-infant attachment problems Post-treatment – Available case analysis (at-risk populations)

Positive mother-infant interaction mean scores Post-treatment – Available case analysis (at-risk populations)

Maternal sensitivity mean scores Post-treatment – Available case analysis (at-risk populations)

Maternal intrusiveness mean scores Post-treatment – Available case analysis (at-risk populations)

Maternal negative engagement mean scores Post-treatment – Available case analysis (at-risk populations)

Infant involvement mean scores Post-treatment – Available case analysis (at-risk populations)

Infant responsivity mean scores Post-treatment – Available case analysis (at-risk populations)

Infant negative engagement/behaviour problems mean score Post-treatment – Available case analysis (at-risk populations)

Discontinued breastfeeding <6 months – ITT analysis (at-risk populations)

Discontinued breastfeeding <6 months – Available case analysis (at-risk populations)

Discontinued breastfeeding <9 months – ITT analysis (at-risk populations)

Discontinued breastfeeding <9 months – Available case analysis (at-risk populations)

Discontinued breastfeeding <12 months – ITT analysis (at-risk populations)

Discontinued breastfeeding <12 months – Available case analysis (at-risk populations)

1.2.21. Mother-infant attachment: Case management and individualised treatment versus TAU

Maternal sensitivity Post-treatment – ITT analysis (at-risk populations)

Maternal sensitivity Post-treatment – Available case analysis (at-risk populations)

1.2.22. Quality of life: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Poor social support Post-treatment – ITT analysis (at-risk populations)

Poor social support Post-treatment – Available case (at-risk populations)

1.2.23. Quality of life: Non-mental health-focused education and support versus TAU or Enhanced TAU

Parental stress mean scores Post-treatment – Available case analysis (at-risk populations)

Social support mean scores Post-treatment – Available case analysis (at-risk populations)

Social support mean scores Short Follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Social support mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.24. Quality of life: Home visits versus TAU

Social support mean scores Post-treatment – Available case analysis (at-risk populations)

Self-esteem mean scores Post-treatment – Available case analysis (at-risk populations)

1.2.25. Quality of life: Mother-infant relationship interventions versus TAU

Parental stress mean scores Post-treatment – Available case analysis (at-risk populations)

Parental stress mean scores Long follow-up (25-104 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.26. Quality of life: Case management and individualised treatment versus TAU

Parental stress mean scores Post-treatment – ITT analysis (at-risk populations)

Parental stress mean scores Post-treatment – Available case analysis (at-risk populations)

Self-esteem mean scores Post-treatment – ITT analysis (at-risk populations)

Self-esteem mean scores Post-treatment – Available case analysis (at-risk populations)

1.2.27. Service utilisation: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Contact with primary and/or secondary care Post-Treatment – ITT analysis (at-risk populations)

Contact with primary and/or secondary care Post-treatment – Available case analysis (at-risk populations)

1.2.28. Service utilisation: Home visits versus TAU

Maternal contact with primary and/or secondary care Post-treatment – ITT analysis (at-risk populations)

Maternal contact with primary and/or secondary care Post-treatment – Available case analysis (at-risk populations)

Infant admissions to hospital Mid-treatment (at 6 months) – ITT analysis (at-risk populations)

Infant length of stay in hospital Mid-treatment (at 6 months) – ITT analysis (at-risk populations)

1.2.29. Experience of care: Non-mental health-focused education and support versus TAU or Enhanced TAU

Maternal dissatisfaction with care Post-treatment – ITT analysis (at-risk populations)

Maternal dissatisfaction with care Post-treatment – Available case analysis (at-risk populations)

1.2.30. Attrition: Post-miscarriage self-help versus TAU

Dropout

1.2.31. Attrition: Social support versus TAU

Dropout

1.2.32. Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Dropout

1.2.33. Attrition: Psychoeducational booklet versus TAU or Enhanced TAU

Dropout

1.2.34. Attrition: Non-mental health-focused education and support versus TAU or Enhanced TAU

Dropout

1.2.35. Attrition: Home visits versus TAU

Dropout

1.2.36. Attrition: Post-delivery discussion versus Enhanced TAU

Dropout

1.2.37. Attrition: Mother-infant relationship interventions versus TAU

Dropout

1.2.38. Infant physical health: Home visits versus TAU

Congenital malformations (measured at 6 months) – Available case analysis (at-risk populations)

Normal weight Post-treatment – Available case analysis (at-risk populations)

Underweight Post-treatment – Available case analysis (at-risk populations)

Overweight Post-treatment – Available case analysis (at-risk populations)

Incidence of severe diarrhoea Post-treatment – Available case analysis (at-risk populations)

1.2.39. Infant regulatory problems: Mother-infant relationship interventions versus TAU

Infant colic mean scores Post-treatment – Available case analysis (at-risk populations)

Infant sleep problems mean score Post-treatment – Available case analysis (at-risk populations)

Infant excessive crying mean scores Post-treatment – Available case analysis (at-risk populations)

Infant colic mean scores Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Infant sleep problems mean score Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

Infant excessive crying mean scores Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.40. Infant physical development: Home visits versus TAU

Infant motor development (delayed or impaired) Post-treatment – ITT analysis (at-risk populations)

Infant motor development (delayed or impaired) Post-treatment – Available case analysis (at-risk populations)

Infant motor development mean scores Post-treatment – Available case analysis (at-risk populations)

Infant motor development (delayed or impaired) Long follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Infant motor development (delayed or impaired) Long follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant motor development mean scores Long follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.41. Infant cognitive development: Home visits versus TAU

Infant cognitive development (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant cognitive development (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant cognitive development mean scores Post-treatment – Available case analysis (at-risk populations)

Infant verbal development (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant verbal development (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant verbal development mean scores Post-treatment – Available case analysis (at-risk populations)

Infant nonverbal development (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant nonverbal development (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant nonverbal development mean scores Post-treatment – Available case analysis (at-risk populations)

Infant spatial reasoning development (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant spatial reasoning development (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant spatial reasoning development mean scores Post-treatment – Available case analysis (at-risk populations)

Infant cognitive development (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Infant cognitive development (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant cognitive development mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant verbal development (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Infant verbal development (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant verbal development mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.42. Infant emotional development: Home visits versus TAU

Infant adaptive behaviour (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant adaptive behaviour (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant adaptive behaviour mean scores Post-treatment – Available case analysis (at-risk populations)

Infant emotional development (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant emotional development (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant externalising (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant externalising (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant externalising mean scores Post-treatment – Available case analysis (at-risk populations)

Infant internalising (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant internalising (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant internalising mean scores Post-treatment – Available case analysis (at-risk populations)

Infant dysregulation (impairment) Post-treatment – ITT analysis (at-risk populations)

Infant dysregulation (impairment) Post-treatment – Available case analysis (at-risk populations)

Infant dysregulation mean scores Post-treatment – Available case analysis (at-risk populations)

Infant adaptive behaviour (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Infant adaptive behaviour (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant adaptive behaviour mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant externalising (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Infant externalising (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant externalising mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant internalising (impairment) Long Follow-up (25-103 weeks post-intervention) – ITT analysis (at-risk populations)

Infant internalising (impairment) Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

Infant internalising mean scores Long Follow-up (25-103 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.43. Infant emotional development: Mother-infant relationship interventions versus TAU

Infant social-communication development mean scores Post-treatment – Available case analysis (at-risk populations)

Infant social withdrawal mean scores Post-treatment – Available case analysis (at-risk populations)

Infant social withdrawal mean scores Short follow-up (9-16 weeks post-intervention) – Available case analysis (at-risk populations)

1.2.44. Prevention of neglect or abuse of the infant: Home visits versus TAU

Child protection issues Post-treatment – ITT analysis (at-risk populations)

Child removed from home Post-treatment – ITT analysis (at-risk populations)

Infant mortality Post-treatment – ITT analysis (at-risk populations)

Infant abuse or neglect Post-treatment – Available case analysis (at-risk populations)

1.3.1. Mental health outcomes for women who saw versus did not see their stillborn infant

Depression symptomatology

Depression mean symptoms

Anxiety symptomatology

Anxiety mean symptoms

PTSD symptomatology

PTSD mean symptoms

Overall adverse outcome

1.3.2. Mental health outcomes for women who held versus did not hold their stillborn infant

Depression symptomatology

Depression mean symptoms

Anxiety symptomatology

Anxiety mean symptoms

PTSD/PTSS symptomatology

PTSD mean symptoms

Overall adverse outcome

1.3.3. Mental health outcomes for women who spent as much time with stillborn infant as they wished versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)

1.3.4. Mental health outcomes for women who kept a photo of their stillborn infant versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)

1.3.5. Mental health outcomes for women who kept a token of remembrance of their stillborn infant versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)

1.3.6. Mental health outcomes for women who took drug to stop milk production following stillbirth versus those who did not

Depression (3-years post-stillbirth; CES-D>90th percentile)

1.4.1. Depression: Structured psychological interventions (CBT or IPT) versus TAU

Depression symptomatology Post-treatment – ITT analysis (no-risk populations)

Depression symptomatology Post-treatment – Available case analysis (no-risk populations)

Depression mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.2. Depression: Listening visits versus TAU

Depression symptomatology Post-treatment – ITT analysis (no-risk populations)

Depression symptomatology Post-treatment – Available case analysis (no-risk populations)

Depression mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.3. Depression: Psychologically (CBT/IPT) – informed psychoeducation versus TAU or Enhanced TAU

Depression symptomatology Post-treatment – ITT analysis (no-risk populations)

Depression symptomatology Post-treatment – Available case analysis (no-risk populations)

Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – ITT analysis (no-risk populations)

Depression symptomatology Short Follow-up (9-16 weeks post-intervention) – Available case analysis (no-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (no-risk populations)

Depression symptomatology Intermediate Follow-up (17-24 weeks post-intervention) – ITT analysis (no-risk populations)

1.4.4. Depression: Home visits versus TAU

Depression mean scores Post-treatment – Available case analysis (no-risk populations)

Depression mean scores Intermediate Follow-up (17-24 weeks post-intervention) – Available case analysis (no-risk populations)

1.4.5. Depression: Post-delivery discussion versus TAU

Depression symptomatology Post-treatment – Available case analysis (no-risk populations)

1.4.6. Depression: Mother-infant relationship interventions versus Enhanced TAU

Depression mean scores Post-treatment – ITT analysis (no-risk populations)

Depression mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.7. Depression: Mindfulness training versus TAU

Depression mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.8. Anxiety: Structured psychological interventions (CBT or IPT) versus TAU

Anxiety mean scores Post-treatment – Available case analysis (no-risk populations)

Trait anxiety mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.9. Anxiety: Listening visits versus TAU

Anxiety mean scores Post-treatment – Available case analysis (no-risk populations)

Trait anxiety mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.10. Anxiety: Post-delivery discussion versus TAU

Anxiety symptomatology Post-treatment – Available case analysis (no-risk populations)

1.4.11. Anxiety: Music therapy versus TAU

Anxiety mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.12. Anxiety: Mindfulness training versus TAU

Anxiety mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.13. General mental health: Structured psychological interventions (CBT or IPT) versus TAU

General mental health mean scores Post-treatment – Available case analysis (no-risk populations)

Risk of self-harm mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.14. General mental health: Listening visits versus TAU

General mental health mean scores Post-treatment – Available case analysis (no-risk populations)

Risk of self-harm mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.15. General mental health: Home visits versus TAU

General mental health mean scores Post-treatment – Available case analysis (no-risk populations)

General mental health mean scores Intermediate follow-up (17-24 weeks post-intervention) – Available case analysis (no-risk populations)

1.4.16. General mental health: Mindfulness training versus TAU

Psychological distress mean scores Post-treatment – Available case analysis (no-risk populations)

Life satisfaction mean scores Post-treatment – Available case analysis (no-risk populations)

Happiness mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.17. Mother-infant attachment: Home visits versus TAU

Discontinued breastfeeding by 6 weeks – Available case analysis (no-risk populations)

Discontinued breastfeeding by 26 weeks – Available case analysis (no-risk populations)

1.4.18. Mother-infant attachment: Mother-infant relationship interventions versus Enhanced TAU

Maternal sensitivity mean scores Post-treatment – ITT analysis (no-risk populations)

Maternal sensitivity mean scores Post-treatment – Available case analysis (no-risk populations)

Child attachment security mean scores Post-treatment – ITT analysis (no-risk populations)

Child attachment security mean scores Post-treatment – Available case analysis (no-risk populations)

Maternal confidence/competence mean scores Post-treatment – ITT analysis (no-risk populations)

Maternal confidence/competence mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.19. Mother-infant attachment: Mindfulness training versus TAU

Maternal confidence/competence mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.20. Quality of life: Structured psychological interventions (CBT or IPT) versus TAU

Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)

Impaired functioning mean scores Post-treatment – Available case analysis (no-risk populations)

Wellbeing mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.21. Quality of life: Listening visits versus TAU

Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)

Impaired functioning mean scores Post-treatment – Available case analysis (no-risk populations)

Wellbeing mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.22. Quality of life: Home visits versus TAU

Social support mean scores Post-treatment – Available case analysis (no-risk populations)

Social support mean scores Intermediate follow-up (17-24 weeks post-intervention) – Available case analysis (no-risk populations)

1.4.23. Quality of life: Mother-infant relationship interventions versus Enhanced TAU

Parental stress mean scores Post-treatment – ITT analysis (no-risk populations)

Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.24. Quality of life: Music therapy versus TAU

Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.25. Quality of life: Mindfulness training versus TAU

Parental stress mean scores Post-treatment – Available case analysis (no-risk populations)

1.4.26. Attrition: Structured psychological interventions (CBT or IPT) versus TAU

Dropout

1.4.27. Attrition: Listening visits versus TAU

Dropout

1.4.28. Attrition: Psychologically (CBT/IPT) – informed psychoeducation versus Enhanced TAU

Dropout

1.4.29. Attrition: Home visits versus TAU

Dropout

1.4.30. Attrition: Mindfulness training versus TAU

Dropout

1.5.1. Depression: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Depression Short Follow-up (diagnosis at 9-16 week follow-up) – ITT analysis

Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – ITT analysis

Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – Available case analysis

Depression Short Follow-up (mean depression symptoms at 9-16 week follow-up) – ITT analysis

Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis

Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis

Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – ITT analysis

Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis

Depression Very long Follow-up (diagnosis at >104 week follow-up) – ITT analysis

Depression Very long Follow-up (diagnosis at >104 week follow-up) – Available case analysis

Depression Very long Follow-up (mean depression symptoms at >104 week follow-up) – Available case analysis

Negative thoughts/mood Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.2. Depression: CBT versus listening visits

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis

1.5.3. Depression: CBT versus Relational Constructivist Therapy

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis

1.5.4. Depression: IPT versus support group

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis

1.5.5. Depression: Facilitated self-help versus TAU

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT Analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

1.5.6. Depression: Post-miscarriage self-help versus TAU

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis

1.5.7. Depression: Post-miscarriage facilitated self-help versus TAU

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis

1.5.8. Depression: Directive counselling versus TAU

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis

1.5.9. Depression: Listening visits versus TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis

Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – by intervention

Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis

Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – ITT analysis

Depression Long Follow-up (symptomatology – above threshold >24 week follow-up) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis

Depression Very long Follow-up (diagnosis at >104 week follow-up) – ITT analysis

Depression Very long Follow-up (diagnosis at >104 week follow-up) – Available case analysis

Depression Very long Follow-up (mean depression symptoms at >104 week follow-up) – Available case analysis

1.5.10. Depression: Post-miscarriage counselling versus TAU

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis

Depression Intermediate follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – ITT analysis

1.5.11. Depression: Post-traumatic birth counselling versus TAU

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

1.5.12. Depression: Social support versus TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – ITT analysis

Depression Short Follow-up (symptomatology – above threshold at 9-16 week follow-up) – Available case analysis

Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis

1.5.13. Depression: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – ITT analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Depression Short Follow-up (mean depression symptoms at 9-16 week follow-up) – ITT analysis

Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis

Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – ITT analysis

Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week followup) – ITT analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis

1.5.14. Depression: IPT-informed psychoeducation versus non-mental health-focused education and support

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT Analysis

1.5.15. Depression: Non-mental health-focused education and support versus TAU

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

1.5.16. Depression: Home visits versus TAU/Enhanced TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

1.5.17. Depression: Mother-infant relationship interventions versus TAU/Enhanced TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) - Available case

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – ITT analysis

Depression Intermediate Follow-up (diagnosis at 17-24 week follow-up) – Available case analysis

Depression Intermediate Follow-up (symptomatology - above threshold at 17-24 week follow-up) – ITT analysis

Depression Intermediate Follow-up (symptomatology - above threshold at 17-24 week follow-up) – Available case analysis

Depression Intermediate Follow-up (mean depression symptoms at 17-24 week follow-up) – Available case analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis

Depression Long Follow-up (diagnosis at >24 week follow-up) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week follow-up) – Available case analysis

Depression Very long Follow-up (diagnosis at >104 week follow-up) – ITT analysis

Depression Very long Follow-up (diagnosis at >104 week follow-up) – Available case analysis

Depression Very long Follow-up (mean depression symptoms at >104 week follow-up) – Available case analysis

1.5.18. Depression: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback

Depression Post-treatment (mean depression symptoms at endpoint or first measurement) – Available case analysis

1.5.19. Depression: Co-parenting intervention versus Enhanced TAU

Depression Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Depression Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

1.5.20. Depression: Infant sleep training (controlled crying) versus TAU/Enhanced TAU

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Depression Short Follow-up (mean depression symptoms or change score at 9-16 week follow-up) – Available case analysis

Depression Long Follow-up (mean depression symptoms at >24 week followup) – Available case analysis

1.5.21. Depression: Music therapy during birth versus TAU

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

1.5.22. Depression: Psychosomatic intervention versus TAU

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Depression Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

1.5.23. Depression: Mindfulness training versus Enhanced TAU

Depression Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

Negative affect Post-treatment (mean depression symptoms at endpoint or first measurement or change score) – Available case analysis

1.5.24. Anxiety: Structured psychological interventions versus TAU/Enhanced TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

Trait anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.25. Anxiety: CBT versus Relational Constructivist Therapy

Anxiety Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.26. Anxiety: IPT versus support group

Anxiety Post-treatment (mean score at endpoint or first measurement) - Available case

1.5.27. Anxiety: Facilitated self-help versus TAU

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.28. Anxiety: Post-miscarriage self-help versus TAU

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

1.5.29. Anxiety: Listening visits versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

Trait anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.30. Anxiety: Directive counselling versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.31. Anxiety: Post-miscarriage counselling versus Enhanced TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

Anxiety Intermediate follow-up (mean anxiety symptoms at 17-24 week follow-up) – Available case analysis

1.5.32. Anxiety: Post-traumatic birth counselling versus TAU

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

1.5.33. Anxiety: Social support versus TAU

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

Anxiety Short follow-up (mean anxiety symptoms at 9-16 week follow-up) – Available case analysis

1.5.34. Anxiety: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Anxiety Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

Anxiety Long Follow-up (diagnosis at >24 week follow-up) – ITT analysis

1.5.35. Anxiety: Mother-infant relationship interventions versus TAU/Enhanced TAU

Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

Anxiety Intermediate follow-up (mean anxiety symptoms at 17-24 week follow-up) – Available case analysis

1.5.36. Anxiety: Music therapy during birth versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.37. Anxiety: Psychosomatic intervention versus TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.38. Anxiety: Mindfulness training versus Enhanced TAU

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – ITT analysis

Anxiety Post-treatment (mean anxiety symptoms at endpoint or first measurement) – Available case analysis

1.5.39. Adjustment disorder: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Adjustment disorders Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Adjustment disorders Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

1.5.40. PTSD: Post-miscarriage self-help versus TAU

PTSD Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

PTSD Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

PTSD Post-treatment (mean score at endpoint or first measurement) – ITT analysis

1.5.41. PTSD: Post-traumatic birth counselling versus TAU

PTSD Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

PTSD Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

PTSD Post-treatment (mean score at endpoint or first measurement) – ITT analysis

PTSD Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.42. PTSD: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

PTSD Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

PTSD Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

PTSD Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.43. PTSD: Mother-infant relationship interventions versus TAU/Enhanced TAU

PTSD Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

PTSD Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

PTSD Post-treatment (mean score at endpoint or first measurement) – Available case analysis

PTSD Intermediate follow-up (symptomatology at 17-24 week follow-up) – ITT analysis

PTSD Intermediate follow-up (symptomatology at 17-24 week follow-up) – Available case analysis

PTSD Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

1.5.44. OCD: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

OCD Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Obsessions Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Compulsions Post-treatment (mean score at endpoint or first measurement) – Available case analysis

OCD Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Obsessions Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Compulsions Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

OCD Long follow-up (mean score at >24 week follow-up) – Available case analysis

Obsessions Long follow-up (mean score at >24 week follow-up) – Available case analysis

Compulsions Long follow-up (mean score at >24 week follow-up) – Available case analysis

1.5.45. Fear of childbirth: Pre-delivery discussion/psychoeducation versus TAU

Elective caesarean Post-treatment (mode of delivery at endpoint) – ITT analysis

Choosing vaginal delivery Post-treatment (delivery preference at endpoint) – ITT analysis

Vaginal delivery Post-treatment (mode of delivery at endpoint) – ITT analysis

Fear of pain in labour Mid-treatment (mean score at mid-treatment [36 weeks gestation]) – ITT analysis

Fear of obstetrician's unfriendly behaviour Mid-treatment (mean score at mid-treatment [36 weeks gestation]) – ITT analysis

Preparedness for childbirth Mid-treatment (mean score at mid-treatment [36 weeks gestation]) – Available case analysis

Satisfaction with childbirth Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Feeling safe during childbirth Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Experience of fear during childbirth Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Maternal attitude to motherhood Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.46. Eating disorder: Mother-infant relationship interventions (and guided self-help) versus listening visits (and guided self-help)

Eating disorder Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Eating disorder Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

1.5.47. General mental health: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

General mental health Post-treatment (mean mental health symptoms at endpoint or first measurement) – ITT analysis

General mental health (higher better) Post-treatment (mean mental health symptoms at endpoint or first measurement) – Available case analysis

Risk of self-harm Post-treatment (mean score at endpoint or first measurement) – Available case analysis

General mental health Short follow-up (mean mental health symptoms at 9-16 week follow-up) – ITT analysis

General mental health Intermediate follow-up (mean mental health symptoms at 17-24 week follow-up) – Available case analysis

1.5.48. General mental health: IPT versus support group

Anger Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.49. General mental health: Post-miscarriage self-help versus TAU

General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – ITT analysis

General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – Available case analysis

General mental health Post-treatment (mean mental health symptoms at endpoint or first measurement) – ITT analysis

1.5.50. General mental health: Listening visits versus TAU

General mental health (higher better) Post-treatment (mean mental health symptoms at endpoint or first measurement) – Available case analysis

Risk of self-harm Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.51. General mental health: Post-miscarriage counselling versus TAU

Self-blame Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Self-blame Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

1.5.52. General mental health: Post-traumatic birth counselling versus TAU

Self-blame Post-treatment (feelings of self-blame at endpoint or first measurement) – ITT analysis

Self-blame Post-treatment (feelings of self-blame at endpoint or first measurement) – Available case analysis

1.5.53. General mental health: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Any psychopathology Post-treatment (diagnosis at endpoint or first measurement) – ITT analysis

Any psychopathology Post-treatment (diagnosis at endpoint or first measurement) – Available case analysis

General mental health Post-treatment (mean mental health symptoms at endpoint or first measurement) – ITT analysis

General mental health Short follow-up (mean mental health symptoms at 9-16 week follow-up) – ITT analysis

1.5.54. General mental health: Home visits versus TAU/Enhanced TAU

General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – ITT analysis

General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – Available case analysis

Alcohol or drug use Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

Alcohol or drug use Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

1.5.55. General mental health: Mother-infant relationship interventions versus TAU/Enhanced TAU

General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – ITT analysis

General mental health Post-treatment (treatment non-response/symptomatology at endpoint or first measurement) – Available case analysis

General mental health (lower better) Post-treatment (mean mental health symptoms at endpoint or first measurement) – Available case analysis

1.5.56. General mental health: Co-parenting intervention versus Enhanced TAU

Psychological distress Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.57. Mother-infant attachment: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

Mother-infant attachment Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Mother-infant play frequency Post-treatment (mothers played with infant once or more every day measured at endpoint or first measurement) – ITT analysis

Mother-infant play frequency Post-treatment (mothers played with infant once or more every day measured at endpoint or first measurement) – Available case analysis

Maternal sensitivity Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – ITT analysis

Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – Available case analysis

Mother-infant attachment Short follow-up (mean score at 9-16 week follow-up) – Available case analysis

Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – ITT analysis

Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – Available case analysis

1.5.58. Mother-infant attachment: Facilitated self-help versus TAU

Maternal attitude towards motherhood Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.59. Mother-infant attachment: Listening visits versus TAU

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – ITT analysis

Discontinued (exclusive) breastfeeding <6 months Post-treatment (stopped breastfeeding before 6 months measured at endpoint or first measurement) – Available case analysis

Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – ITT analysis

Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – Available case analysis

1.5.60. Mother-infant attachment: Social support versus TAU

Mother-infant feeding interaction Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Mother-infant teaching interaction Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.61. Mother-infant attachment: Psychologically (CBT/IPT) - informed psychoeducation versus Enhanced TAU

Maternal competence/confidence Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Maternal competence/confidence Short follow-up (mean score at 9-16 week follow-up) – Available case analysis

1.5.62. Mother-infant attachment: Home visits versus TAU/Enhanced TAU

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

1.5.63. Mother-infant attachment: Mother-infant relationship interventions versus TAU/Enhanced TAU

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant attachment problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

Mother-infant attachment/positive interactions Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Maternal sensitivity Post-treatment (treatment response at endpoint or first measurement) – ITT analysis

Maternal sensitivity Post-treatment (treatment response at endpoint or first measurement) – Available case analysis

Maternal sensitivity Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Maternal structuring Post-treatment (treatment response at endpoint or first measurement) – ITT analysis

Maternal structuring Post-treatment (treatment response at endpoint or first measurement) – Available case analysis

Maternal structuring Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Maternal nonintrusiveness Post-treatment (treatment response at endpoint or first measurement) – ITT analysis

Maternal nonintrusiveness Post-treatment (treatment response at endpoint or first measurement) – Available case analysis

Maternal nonintrusive behaviour Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Maternal intrusive behaviour Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Maternal nonhostility Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Child responsiveness Post-treatment (treatment response at endpoint or first measurement) – ITT analysis

Child responsiveness Post-treatment (treatment response at endpoint or first measurement) – Available case analysis

Child responsiveness Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Child involvement Post-treatment (treatment response at endpoint or first measurement) – ITT analysis

Child involvement Post-treatment (treatment response at endpoint or first measurement) – Available case analysis

Child involvement/positive engagement Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Child attachment security Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – ITT analysis

Mother-infant behaviour management problems Post-treatment (number with adverse events measured at endpoint or first measurement) – Available case analysis

Maternal confidence/competence Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Mother-infant positive interaction Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Maternal sensitivity Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Maternal intrusive behaviour Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – ITT analysis

Mother-infant attachment problems Long follow-up (number with adverse events measured at >24 week follow-up) – Available case

Maternal sensitivity Long follow-up (mean score at >24 week follow-up) – Available case analysis

Maternal structuring Long follow-up (mean score at >24 week follow-up) – Available case analysis

Maternal nonintrusive behaviour Long follow-up (mean score at >24 week follow-up) – Available case analysis

Maternal nonhostility Long follow-up (mean score at >24 week follow-up) – Available case analysis

Child responsiveness Long follow-up (mean score at >24 week follow-up) – Available case analysis

Child involvement Long follow-up (mean score at >24 week follow-up) – Available case analysis

Mother-infant attachment/positive interactions Very long follow-up (mean score at >104 week follow-up) – Available case analysis

Child attachment security Very long follow-up (mean score at >104 week follow-up) – Available case analysis

1.5.64. Mother-infant attachment: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback

Maternal confidence Post-treatment (mean scores at endpoint or first measurement) – Available case analysis

Maternal perceptions of infant behaviour Post-treatment (mean scores at endpoint or first measurement) – Available case analysis

1.5.65. Mother-infant attachment: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)

Mealtime conflict Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis

Mealtime conflict Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis

Maternal inappropriate verbal responses Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis

Maternal inappropriate verbal responses Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis

Maternal intrusions Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis

Maternal intrusions Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis

Infant autonomy Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – ITT analysis

Infant autonomy Post-treatment (behavioural observation of mealtime at endpoint or first measurement) – Available case analysis

1.5.66. Quality of life: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Social support Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Life functioning Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Life functioning Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Wellbeing Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Social support Short follow-up (mean score at 9-16 week follow-up) – ITT analysis

Social support Short follow-up (mean score at 9-16 week follow-up) – Available case analysis

Life functioning Short follow-up (mean score at 9-16 week follow-up) – ITT analysis

1.5.67. Quality of life: IPT versus support group

Maternal cortisol level Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.68. Quality of life: Facilitated self-help versus TAU

Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Functional impairment Post-treatment (mean score at endpoint or first measurement) - Available analysis

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

1.5.69. Quality of life: Listening visits versus TAU

Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Wellbeing Post-treatment (improved wellbeing at endpoint or first measurement) – Available case analysis

Wellbeing Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.70. Quality of life: Directive counselling versus TAU

Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

1.5.71. Quality of life: Post-miscarriage counselling versus TAU

Functional impairment Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.72. Quality of life: Post-traumatic birth counselling versus TAU

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

1.5.73. Quality of life: Social support versus TAU

Social support Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Maternal cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Self-esteem Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Loneliness Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Loneliness Short follow-up (mean score at 9-16 week follow-up) – Available case analysis

1.5.74. Quality of life: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Social support Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Functional impairment Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

Maternal cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Happiness Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Social support Short follow-up (mean score at 9-16 week follow-up) – ITT analysis

Functional impairment Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Parental stress Intermediate follow-up (mean score at 17-24 week follow-up) – ITT analysis

Parental stress Intermediate follow-up (mean score at 17-24 week follow-up) – Available case analysis

Happiness Intermediate follow-up (mean score at 17-24 week follow-up) – ITT analysis

Parental stress Long follow-up (mean score at >24 week follow-up) – Available case analysis

Maternal cortisol levels Long follow-up (mean score at >24 week follow-up) – Available case analysis

1.5.75. Quality of life: Home visits versus TAU/Enhanced TAU

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

1.5.76. Quality of life: Mother-infant relationship interventions versus TAU/Enhanced TAU

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – ITT analysis

Parental stress Post-treatment (symptomatology at endpoint or first measurement) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement or change score) – Available case analysis

1.5.77. Quality of life: Psychosomatic intervention versus TAU

Poor social support Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Parental stress Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.78. Quality of life: Mindfulness training versus TAU/Enhanced TAU

Parental stress Post-treatment (mean score at endpoint or first measurement) – ITT analysis

Parental stress Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Positive affect Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.79. Service utilisation: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis

Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis

Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – ITT analysis

Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – Available case analysis

Psychotherapy Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis

Psychotherapy Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis

Counselling Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis

Counselling Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis

Self-help support group Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis

Self-help support group Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis

Alternative therapies Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis

Alternative therapies Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis

1.5.80. Service utilisation: Facilitated self-help versus TAU

Use of childbirth hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Use of childbirth hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of childbirth hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of mental health hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Use of mental health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of mental health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of mental health outpatient Post-Treatment (service utilisation at endpoint) – ITT analysis

Use of mental health outpatient Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of mental health outpatient Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of health community service Post-Treatment (service utilisation at endpoint) – ITT analysis

Use of health community service Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of health community service Post-Treatment (service utilisation at endpoint) – Available case analysis

Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – ITT analysis

Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – Available case analysis

Antidepressant medication Post-Treatment (medication use at endpoint) – Available case analysis

1.5.81. Service utilisation: Listening visits versus TAU

Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Use of maternal general health hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – ITT analysis

Use of NHS health visitor Post-Treatment (service utilisation at endpoint or first measurement) – Available case analysis

Health visitor telephone contact Post-Treatment (service utilisation [in last month] at endpoint) – ITT analysis

Health visitor telephone contact Post-Treatment (service utilisation [in last month] at endpoint) – Available case analysis

Maternal use of midwife Post-Treatment (service utilisation [in last month] at endpoint) – ITT analysis

Maternal use of midwife Post-Treatment (service utilisation [in last month] at endpoint) – Available case analysis

Use of GP Post-Treatment (service utilisation [in last month] at endpoint) – ITT analysis

Use of GP Post-Treatment (service utilisation [in last month] at endpoint) – Available case analysis

1.5.82. Service utilisation: Social support versus TAU

Health service use Post-Treatment (service utilisation at endpoint) – Available case analysis

Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – ITT analysis

Antidepressant medication Post-Treatment (medication use at endpoint or first measurement) – Available case analysis

Health service use Short follow-up (service utilisation at 9-16 week follow-up) – Available case analysis

Antidepressant medication Short follow-up (medication use at 9-16 week follow-up) – ITT analysis

Antidepressant medication Short follow-up (medication use at 9-16 week follow-up) – Available case analysis

1.5.83. Experience of care: Mother-infant relationship interventions versus TAU/Enhanced TAU

Satisfaction with intervention Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Satisfaction with therapeutic alliance (empathetic) Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.84. Attrition: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Dropout

1.5.85. Attrition: CBT versus Relational Constructivist Therapy

Dropout

1.5.86. Attrition: IPT versus support group

Dropout

1.5.87. Attrition: Facilitated self-help versus TAU

Dropout

1.5.88. Attrition: Listening visits versus TAU

Dropout

1.5.89. Attrition: Directive counselling versus TAU

Dropout

1.5.90. Attrition: Post-miscarriage counselling versus TAU/Enhanced TAU

Dropout

1.5.91. Attrition: Post-traumatic birth counselling versus TAU

Dropout

1.5.92. Attrition: Social support versus TAU

Dropout

1.5.93. Attrition: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Dropout

1.5.94. Attrition: Non-mental health-focused education and support versus TAU

Dropout

1.5.95. Attrition: Home visits versus TAU

Dropout

1.5.96. Attrition: Mother-infant relationship interventions versus TAU/Enhanced TAU

Dropout

1.5.97. Attrition: Mother-infant relationship intervention with video feedback versus mother-infant relationship intervention with verbal feedback

Dropout

1.5.98. Attrition: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)

Dropout

1.5.99. Attrition: Co-parenting intervention versus Enhanced TAU

Dropout

1.5.100. Attrition: Music therapy during birth versus TAU

Dropout

1.5.101. Attrition: Psychosomatic intervention versus TAU

Dropout

1.5.102. Attrition: Mindfulness training versus Enhanced TAU

Dropout

1.5.103. Infant service use: Facilitated self-help versus TAU

Infant hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

1.5.104. Infant service use: Listening visits versus TAU

Infant hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Visit to A&E Post-Treatment (service utilisation measured at endpoint) – ITT analysis

Visit to A&E Post-Treatment (service utilisation measured at endpoint) – Available case analysis

Visit to NHS health visitor at clinic Post-Treatment (service utilisation [in past month] at endpoint) – ITT analysis

Visit to NHS health visitor at clinic Post-Treatment (service utilisation [in past month] at endpoint) – Available case analysis

Visit from NHS health visitor at home Post-Treatment (service utilisation [in past month] at endpoint) - by intervention

Visit from NHS health visitor at home Post-Treatment (service utilisation [in past month] at endpoint) - by intervention

Visit to GP Post-Treatment (service utilisation [in past month] at endpoint) – ITT analysis

Visit to GP Post-Treatment (service utilisation [in past month] at endpoint) – Available case analysis

Any medication Post-Treatment (medication use [in past week] at endpoint) – ITT analysis

Any medication Post-Treatment (past medication use measured at endpoint) – by intervention

Antibiotics Post-Treatment (medication use [in past week] at endpoint) – ITT analysis

Antibiotics Post-Treatment (medication use [in past week] at endpoint) – Available case analysis

Asthma medication Post-Treatment (medication use [in past week] at endpoint) – ITT analysis

Asthma medication Post-Treatment (medication use [in past week] at endpoint) – Available case analysis

Skin ointment Post-Treatment (medication use [in past week] at endpoint) – ITT analysis

Skin ointment Post-Treatment (medication use [in past week] at endpoint) – Available case analysis

Visit to A&E Long follow-up (service utilisation [in past month] at >24 week follow-up) – ITT analysis

Visit to A&E Long follow-up (service utilisation [in past month] at >24 week follow-up) – Available case analysis

Visit to NHS health visitor at clinic Long follow-up (service utilisation [in past month] at >24 week follow-up) – Available case analysis

Visit to GP Long follow-up (service utilisation [in past month] at >24 week follow-up) – ITT analysis

Visit to GP Long follow-up (service utilisation [in past month] at >24 week follow-up) – Available case analysis

1.5.105. Infant service use: Home visits versus TAU

Infant hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Visit to A&E Post-Treatment (service utilisation measured at endpoint) – ITT analysis

Visit to A&E Post-Treatment (service utilisation measured at endpoint) – Available case analysis

Any medication Post-Treatment (past medication use measured at endpoint) – Available case analysis

1.5.106. Infant service use: Mother-infant relationship interventions versus TAU/Enhanced TAU

Infant hospital Post-Treatment (service utilisation at endpoint) – ITT analysis

Infant hospital Post-Treatment (service utilisation at endpoint) – Available case analysis

Contact with specialised healthcare services Post-Treatment (service utilisation at endpoint) – ITT analysis

Contact with specialised healthcare services Post-Treatment (service utilisation at endpoint) – Available case analysis

Contact with developmental/rehabilitation specialist Post-Treatment (service utilisation at endpoint) – ITT analysis

Contact with developmental/rehabilitation specialist Post-Treatment (service utilisation at endpoint) – Available case analysis

Any medication Post-Treatment (medication use [in past week] at endpoint) – ITT analysis

Any medication Post-Treatment (past medication use measured at endpoint) – Available case analysis

Surgery Post-Treatment (service utilisation at endpoint) – ITT analysis

Surgery Post-Treatment (service utilisation at endpoint) – Available case analysis

Oxygen therapy Post-Treatment (service utilisation at endpoint) – ITT analysis

Oxygen therapy Post-Treatment (service utilisation at endpoint) – Available case analysis

1.5.107. Infant physical health: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Underweight Post-treatment (underweight at endpoint or first measurement) – ITT analysis

Underweight Post-treatment (underweight at endpoint or first measurement) – Available case analysis

Weight-for-age Post-treatment (mean z score at endpoint or first measurement) – Available case analysis

Stunted height Post-treatment (short-for-age at endpoint or first measurement) – ITT analysis

Stunted height Post-treatment (short-for-age at endpoint or first measurement) – Available case analysis

Height-for-age Post-treatment (mean z score at endpoint or first measurement) – Available case analysis

Diarrhoea Post-treatment (=>1 diarrhoea episodes [in past 2 weeks] at endpoint or first measurement) – ITT analysis

Diarrhoea Post-treatment (=>1 diarrhoea episodes [in past 2 weeks] at endpoint or first measurement) – Available case analysis

1.5.108. Infant physical health: IPT versus support group

Gestational age Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Birth weight Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.109. Infant physical health: Listening visits versus TAU

Ill health Post-treatment (maternal concerns about child health at endpoint or first measurement) – ITT analysis

Ill health Post-treatment (maternal concerns about child health at endpoint or first measurement) – Available case analysis

1.5.110. Infant physical health: Social support versus TAU

Infant cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.111. Infant physical health: Psychologically (CBT/IPT) - informed psychoeducation versus TAU/Enhanced TAU

Infant stress Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant cortisol levels Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant cortisol levels Long follow-up (mean score at >24 week follow-up) – Available case analysis

1.5.112. Infant physical health: Mother-infant relationship intervention (and guided self-help) versus listening visits (and guided self-help)

Weight-for-age Post-treatment (mean z score at endpoint or first measurement) – Available case analysis

1.5.113. Infant physical development: CBT versus listening visits

Infant motor development Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.114. Infant physical development: Listening visits versus TAU

Infant eating habits Post-treatment (maternal concerns at endpoint or first measurement) – ITT analysis

Infant eating habits Post-treatment (maternal concerns at endpoint or first measurement) – Available case analysis

Infant sleeping habits Post-treatment (maternal concerns at endpoint or first measurement) – ITT analysis

Infant sleep problems Post-treatment (maternal report at endpoint or first measurement) – Available case analysis

1.5.115. Infant physical development: Home visits versus TAU

Infant motor development Post-treatment (below threshold at endpoint or first measurement) – ITT analysis

Infant motor development Post-treatment (below threshold at endpoint or first measurement) – Available case analysis

Infant feeding problems Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant sleep problems Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.116. Infant physical development: Mother-infant relationship interventions versus TAU/Enhanced TAU

Infant motor development Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.117. Infant physical development: Infant sleep training (controlled crying) versus TAU

Infant sleep problems Post-treatment (maternal report at endpoint or first measurement) – Available case analysis

Infant sleep problems Short follow-up (maternal report at 9-16 week follow-up) – Available case analysis

Infant sleep problems Long follow-up (maternal report at >24 week follow-up) – Available case analysis

1.5.118. Infant cognitive development: CBT versus listening visits

Infant cognitive development Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.119. Infant cognitive development: Listening visits versus TAU

Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – ITT analysis

Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – Available case analysis

Infant verbal development Post-treatment (maternal concerns at endpoint or first measurement) – ITT analysis

Infant verbal development Post-treatment (maternal concerns at endpoint or first measurement) – Available case analysis

1.5.120. Infant cognitive development: Social support versus TAU

Infant cognitive development Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.121. Infant cognitive development: Home visits versus TAU

Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – ITT analysis

Infant cognitive development Post-treatment (maternal concerns/below threshold at endpoint or first measurement) – Available case analysis

1.5.122. Infant cognitive development: Mother-infant relationship interventions versus TAU/Enhanced TAU

Infant cognitive development Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant verbal development Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.123. Infant emotional development: Social support versus TAU

Infant ‘difficult’ temperament Post-treatment (maternal-rated mean score at endpoint or first measurement) – Available case analysis

1.5.124. Infant emotional development: Home visits versus TAU

Infant externalising Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Infant externalising Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Infant internalising Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Infant internalising Post-treatment (symptomatology - above threshold at endpoint or first measurement) – Available case analysis

Infant social withdrawal Post-treatment (symptomatology - above threshold at endpoint or first measurement) – ITT analysis

Infant social withdrawal Post-treatment (symptomatology – above threshold at endpoint or first measurement) – Available case analysis

Infant social withdrawal Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.125. Infant emotional development: Mother-infant relationship interventions versus TAU/Enhanced TAU

Infant adaptive behaviour Post-treatment (treatment response at endpoint or first measurement) – ITT analysis

Infant adaptive behaviour Post-treatment (treatment response at endpoint or first measurement) – Available case analysis

Infant adaptive behaviour Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant externalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant internalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant dysregulation Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant self-esteem Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant externalising Very long Follow-up (mean score at >104 week follow-up) – Available case analysis

Infant internalising Very long Follow-up (mean score at >104 week follow-up) – Available case analysis

1.5.126. Infant emotional development: Infant sleep training (controlled crying) versus TAU

Infant externalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis

Infant internalising Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.127. Prevention of neglect or abuse of the infant: Listening visits versus TAU

Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – ITT analysis

Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – Available case analysis

Child injury Long follow-up (Injury requiring medical attention at >24 week follow-up) – ITT analysis

Child injury Long follow-up (Injury requiring medical attention at >24 week follow-up) - by intervention

1.5.128. Prevention of neglect or abuse of the infant: Home visits versus TAU

Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – ITT analysis

Child injury Post-treatment (Injury requiring medical attention at endpoint or first measurement) – Available case analysis

Ingestion of poison Post-treatment (incidence during trial measured at endpoint or first measurement) – Available case analysis

Child protective service reports (all types) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – ITT analysis

Child protective service reports (all types) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – Available case analysis

Child protective service reports (neglect) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – ITT analysis

Child protective service reports (neglect) Post-treatment (substantiated reports during trial measured at endpoint or first measurement) – Available case analysis

Maternal use of punishment Post-treatment (corporate/verbal punishment used anytime in past week measured at endpoint or first measurement) – ITT analysis

Maternal use of punishment Post-treatment (corporate/verbal punishment used anytime in past week measured at endpoint or first measurement) – Available case analysis

Potential for child abuse Post-treatment (mean score at endpoint or first measurement) – Available case analysis

1.5.129. Optimal infant care: Structured psychological interventions (CBT or IPT) versus TAU/Enhanced TAU

Immunisation Post-treatment (complete immunisation at endpoint or first measurement) – ITT analysis

Immunisation Post-treatment (complete immunisation at endpoint or first measurement) – Available case analysis

1.6.1. Depression: Omega-3 versus placebo

Depression mean symptoms - Post-treatment - score at endpoint or first measurement (no risk populations)

Depression mean symptoms - Short follow-up - score at long-term (60 week) follow-up (no risk populations)

Depression symptomology - Post-treatment - above threshold at endpoint or first measurement (no risk populations)

Depression symptomology - Post-treatment - above threshold at intermediate (24 week) follow-up (no risk populations)

Depression diagnosis – Post-treatment – current depression, new or existing during study period (no risk populations)

1.6.2. Depression: Selenium versus placebo

Depression mean scores - Post-treatment - score at endpoint or first measurement (no risk populations)

1.6.3. Depression: Calcium versus placebo

Depression mean scores - Post-treatment - score at short-term (9-16 weeks) follow-up (no risk factors)

Depression symptomology - Post-treatment - score at endpoint or first measurement (no risk populations)

Depression symptomology – Post-treatment – above threshold at short-term (9-16 weeks) follow-up (no risk populations)

1.6.4. Compliance: Selenium versus placebo

Compliance - Post-treatment - serum selenium concentrations at endpoint or first measurement (no risk populations)

1.6.5. Quality of life: Calcium versus placebo

Quality of life - Post-treatment - positive life events at first measurement (no risk populations)

Quality of life - Post-treatment - negative life events at first measurement (no risk populations)

1.6.6. Infant outcomes: Omega-3 versus placebo

Infant outcomes - Post-treatment - mean scores on the Bayley scales of Infant Development at long-term (78 weeks) follow - up (no risk populations)

Infant outcomes - Post-treatment - delayed cognitive performance at long term (78 weeks) follow-up (no risk populations)

Infant outcomes – Post-treatment – delayed language performance at long term (78 weeks) follow-up (no risk populations)

1.6.7. Leaving the study early: Omega-3 versus placebo

Leaving the study early - Post-treatment - end of the intervention (no risk populations)

1.6.8. Adverse events/ Service utilisation: Omega-3 versus placebo

Maternal hospitalisation for serious adverse events - Post-treatment - end of the intervention or first measurement (no risk populations)

Infant admission to neonatal intensive care hospitalisation for serious adverse events - Post-treatment - end of the intervention or first measurement (no risk populations)

Major congenital abnormality of the infant - Post-treatment - long-term (78 weeks) follow-up (no risk populations)

1.7.1. Depression: Thyroxine versus placebo

Depression symptomology - Post-treatment - above threshold at endpoint or first measurement (risk populations)

Depression diagnosis – Post treatment – major depression (definite and probable cases) at endpoint or first measurement (risk populations)

Depression diagnosis - Post treatment - any depression diagnosis at endpoint or first measurement (risk populations)

1.7.2. Depression: Norethisterone versus placebo

Depression mean scores - Post treatment - at endpoint or first measurement (risk populations)

Depression mean scores - Post treatment - at short-term follow-up (risk populations)

Depression symptomology – Post treatment – at endpoint or first measurement (risk populations)

Depression symptomology - Post treatment - above depression threshold at short-term (9-16 week) follow-up (risk populations)

1.7.3. Compliance: Thyroxine versus placebo

Compliance - Post-treatment - numbers not compliant at endpoint or first measurement (risk populations)

1.7.4. Mother-Infant interaction: Norethisterone versus placebo

Breastfeeding - Post-treatment - exclusive or partial breastfeeding at endpoint or first measurement (risk populations)

Breastfeeding – Post-treatment – exclusive or partial breastfeeding at short term (13 weeks) follow-up (risk populations)

1.7.5. Leaving the study early: Norethisterone versus placebo

Leaving the study early - Post-treatment - end of the intervention (risk populations)

Leaving the study early - Post-treatment short-term (17-19 weeks) follow-up (risk populations)

1.7.6. Adverse events: Norethisterone versus placebo

Vaginal bleeding - Post treatment - number of days at endpoint or first measurement (risk populations)

Vaginal bleeding – Post treatment – number of days at short-term follow-up (risk populations)

Troublesome bleeding - Post treatment - number at endpoint or first measurement (risk populations)

Sexual interest - Post treatment - no return of sexual interest at endpoint or first measurement (risk populations)

1.8.1. Depression: SSRI (Sertraline) versus placebo

Recurrence of depression - Post-treatment - number at endpoint or first measurement (prophylaxis)

1.8.2. Depression: TCA (Nortriptyline) versus placebo

Recurrence of depression - Post-treatment - number at endpoint or first measurement (prophylaxis)

Recurrence of depression - Post-treatment - number at long-term (25-103 weeks) follow-up (prophylaxis)

1.8.3. Adverse events: SSRI (Sertraline) versus placebo

Dizziness - Post-treatment - number at endpoint or first measurement (prophylaxis)

Drowsiness - Post-treatment - number at endpoint or first measurement (prophylaxis)

1.8.4. Adverse events: TCA (Nortriptyline) versus placebo

Discontinuation due to adverse events - Post treatment - number at endpoint or first measurement (prophylaxis)

Constipation – Post treatment – number at endpoint or first measurement (prophylaxis)

1.8.5. Leaving the study early: SSRI (Sertraline) versus placebo

Leaving the study early for any reason except recurrence - Post-treatment - number at endpoint (prophylaxis)

1.8.6. Leaving the study early: TCA (Nortriptyline) versus placebo

Leaving the study early for any reason except recurrence - Post-treatment - number at endpoint (prophylaxis)

1.9.1. Non-Response: Omega-3 versus Placebo

Non-response - Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

Non-response – Post-treatment – number at endpoint or first measurement – ITT analysis (treatment)

Non-remission - Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

1.9.2. Non-response to treatment: SSRIs (sertraline/paroxetine) versus placebo

Non-response - Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

Non-response - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

Non-remission - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

1.9.3. Non-response to treatment: SSRIs in combination with psychological interventions compared with placebo in combination with psychological interventions

Non-response - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

Non-remission – Post-treatment – number at endpoint or first measurement – ITT analysis (treatment)

1.9.4. Non-response to treatment: SSRIs verses TCA

Non-response - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

Non-response - Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

Non-remission – Post-treatment – number at endpoint or first measurement – ITT analysis (treatment)

Non-remission – Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)

Non-response - Post-treatment - number at intermediate follow-up (20-24 weeks - end of continuation phase) – ITT analysis (treatment)

Non-response - Post-treatment - number at intermediate follow-up (20-24 weeks - end of continuation phase) – Available case analysis (treatment)

1.9.5. Depression: SSRIs versus Placebo

Mean depression scores Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

1.9.6. Depression: SSRIs versus TCA

Mean depression scores Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

Mean depression scores - Post-treatment - number at intermediate follow-up – Available case analysis (treatment)

1.9.7. Depression: SSRIs in combination with psychological interventions compared with placebo in combination with psychological interventions

Mean depression scores - Post-treatment - score at endpoint or first measurement – Available case analysis (treatment)

Mean depression scores Post-treatment – score at endpoint or first measurement – ITT analysis (treatment)

1.9.8. Depression: Antidepressants versus general supportive care

Depression symptomology Post-treatment-above depression threshold at endpoint or first measurement – Available case analysis (treatment)

Depression symptomology Post-treatment-above depression threshold at endpoint or first measurement - ITT analysis (treatment)

Mean depression scores - Post-treatment-above depression threshold at endpoint or first measurement – Available case analysis (treatment)

1.9.9. Depression: Omega-3 versus Placebo

Mean depression scores Post-treatment – score at endpoint or first measurement – ITT analysis (treatment)

1.9.10. Depression: Hormones (transdermal oestrogen) versus placebo

Depression symptomology - Post-treatment - score at endpoint or first measurement - ITT analysis (treatment)

Depression symptomology - Post-treatment - score at endpoint or first measurement – Available case analysis (treatment)

1.9.11. General mental health: SSRIs versus TCA

Mean global assessment of functioning - Post-treatment - score at endpoint or first measurement – Available case analysis (treatment)

Social problems Post-treatment – number at endpoint or first measurement – Available case analysis (treatment)

Mean global assessment of functioning – Post-treatment – score at Intermediate follow-up – Available case analysis (treatment)

Social problems Post-treatment - number at Intermediate follow-up – Available case analysis (treatment)

Global severity and improvement - Post-treatment - number at endpoint or first measurement – Available case analysis (treatment)

1.9.12. General mental health: SSRIs combined with psychosocial interventions versus placebo combined with psychosocial interventions

Global severity – Post-treatment – mean scores at endpoint or first measurement – ITT analysis (treatment)

Global Improvement – Post-treatment – mean scores at endpoint or first measurement – ITT analysis (treatment)

Distress - Post-treatment - mean scores at endpoint or first measurement – Available case analysis (treatment)

Distress - Post-treatment - mean scores at endpoint or first measurement - ITT analysis (treatment)

1.9.13. General mental health: SSRIs compared with placebo

Global severity and improvement - Post-treatment - mean scores at endpoint or first measurement – available case analysis (treatment)

1.9.14. Service utilisation: SSRIs combined with psychosocial interventions compared with Placebo combined with psychosocial interventions

Loranzepam use - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

1.9.15. Service Utilisation: SSRIs compared with Placebo

Benzodiazepine use - Post-treatment - number at endpoint or first measurement - ITT analysis (treatment)

1.9.16. Leaving the Study early: SSRIs combined with psychological interventions compared with Placebo combined with psychological interventions

Leaving the study early due to adverse events – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)

Leaving the study early due for any reason – Post-treatment number at endpoint or first measurement – Available case analysis (treatment)

1.9.17. Leaving the Study early: SSRIs compared with Placebo

Leaving the study early due for any reason - Post-treatment number at endpoint or first measurement – Available case analysis (treatment)

1.9.18. Leaving the Study early: SSRIs compared with TCAs

Leaving the study early due for any reason - Post-treatment number at endpoint or first measurement – Available case analysis (treatment)

1.9.19. Leaving the Study early: Hormones versus placebo

Leaving the study early due for any reason - Post-treatment number at endpoint or first measurement – Available case analysis (treatment)

1.9.20. Leaving the Study early: Omega-3 versus Placebo

Leaving the study early due for any reason - Post-treatment number at endpoint or first measurement – Available case analysis (treatment)

1.9.21. Adverse events: SSRI combined with psychosocial interventions compared with Placebo compared with psychosocial interventions

Major adverse events (hypomanic switch) - Post-treatment number at endpoint or first measurement - ITT analysis (treatment)

Side events (hypomanic switch) – Post-treatment mean score at endpoint or first measurement – ITT analysis (treatment)

1.9.22. Adverse events: omega-3 versus placebo

Possible hypomanic side effects - Post-treatment mean score at endpoint or first measurement – Available case analysis (treatment)

Suicide - Post-treatment mean score at endpoint or first measurement – Available case analysis (treatment)

Any mild/transient side effects - Post-treatment mean score at endpoint or first measurement – Available case analysis (treatment)

1.9.23. Adverse events: SSRIs versus placebo

Decreased appetite - Post-treatment - number at endpoint or first measurement – Available case analysis

Diarrhoea - Post-treatment - number at endpoint or first measurement – Available case analysis

Dizziness - Post-treatment - number at endpoint or first measurement – Available case analysis

Headache – Post-treatment – number at endpoint or first measurement – Available case analysis

Nausea - Post-treatment - number at endpoint or first measurement – Available case analysis

Somnolence - Post-treatment - number at endpoint or first measurement – Available case analysis

Dry mouth - Post-treatment - number at endpoint or first measurement – Available case analysis

1.9.24. Compliance: SSRIs versus Placebo

Non - compliance - Post-treatment - number at endpoint or first measurement – Available case analysis

1.10.1. Antidepressants: Teratogenic harms

SSRIs - Teratogenic harms - Congenital malformations-cohort design

SSRIs - Teratogenic harms - Congenital malformations-case control design

TCAs – Teratogenic harms – Congenital malformations-cohort design

Paroxetine – Teratogenic harms – Congenital malformations-cohort design

Citalopram - Teratogenic harms - Congenital malformations-cohort design

Fluoxetine - Teratogenic harms - Congenital malformations-cohort design

Sertraline – Teratogenic harms – Congenital malformations-cohort design

Fluvoxamine - Teratogenic harms - Congenital malformations-cohort design

Escitalopram - Teratogenic harms - Congenital malformations-cohort design

Venlafaxine – Teratogenic harms – Congenital malformations-cohort design

Any antidepressant - Teratogenic harms - Major congenital malformations- case-cohort design

SSRIs - Teratogenic harms - Major congenital malformations-cohort design

Paroxetine – Teratogenic harms – Major congenital malformations-cohort design

Citalopram - Teratogenic harms - Major congenital malformations-cohort design

Fluoxetine - Teratogenic harms - Major congenital malformations-cohort design

Sertraline – Teratogenic harms – Major congenital malformations-cohort design

Fluvoxamine - Teratogenic harms - Major congenital malformations-cohort design

Escitalopram - Teratogenic harms - Major congenital malformations-cohort design

Venlafaxine - Teratogenic harms - Major congenital malformations-cohort design

SSRIs – Teratogenic harms – Cardiac malformations-cohort design

TCAs - Teratogenic harms - Cardiac malformations-cohort design

Paroxetine - Teratogenic harms - Cardiac malformations-cohort design

Paroxetine – Teratogenic harms – Cardiac malformations-case-cohort design

Citalopram - Teratogenic harms - Cardiac malformations-cohort design

Fluoxetine - Teratogenic harms - Cardiac malformations-cohort design

Sertraline - Teratogenic harms - Cardiac malformations-cohort design

Fluvoxamine – Teratogenic harms – Cardiac malformations-cohort design

Escitalopram - Teratogenic harms - Cardiac malformations-cohort design

Venlafaxine - Teratogenic harms - Cardiac malformations-cohort design

SSRIs – Teratogenic harms – ASD and/or VSD-cohort design

Paroxetine – Teratogenic harms – ASD and/or VSD-cohort design

Citalopram - Teratogenic harms - ASD and/or VSD-cohort design

Fluoxetine - Teratogenic harms - ASD and/or VSD-cohort design

Sertraline – Teratogenic harms – ASD and/or VSD-cohort design

Fluvoxamine – Teratogenic harms – ASD and/or VSD-cohort design

Escitalopram - Teratogenic harms - ASD and/or VSD-cohort design

SSRIs - Teratogenic harms - ASD-cohort design

Paroxetine – Teratogenic harms – ASD-cohort design

Citalopram – Teratogenic harms – ASD-cohort design

Fluoxetine - Teratogenic harms - ASD-cohort design

Sertraline - Teratogenic harms - ASD-cohort design

Fluvoxamine - Teratogenic harms - ASD-cohort design

Escitalopram - Teratogenic harms - ASD-cohort design

SSRIs – Teratogenic harms – VSD-cohort design

Paroxetine - Teratogenic harms - VSD-cohort design

Citalopram - Teratogenic harms - VSD-cohort design

Fluvoxamine - Teratogenic harms - VSD-cohort design

Sertraline - Teratogenic harms - VSD-cohort design

Fluvoxamine - Teratogenic harms - VSD-cohort design

Escitalopram - Teratogenic harms - VSD-cohort design

1.10.2. Antidepressants: Neonatal and obstetric complications

SSRIs – Neonatal and obstetric complications – Miscarriage-cohort design

SSRIs – Neonatal and obstetric complications – Pre-term delivery-cohort design

Any antidepressant - Neonatal and obstetric complications - PNAS-cohort design

SSRIs - PPHT - Neonatal and obstetric complications - Cohort design

Any antidepressant – Respiratory distress – Neonatal and obstetric complications – Cohort design

Any antidepressant - Tremors - Neonatal and obstetric complications - Cohort design

1.10.3. Antipsychotics: Teratogenic harms

Any antipsychotic - Teratogenic harms-Congenital malformations - Cohort design

Any antipsychotic – Teratogenic harms-Major congenital malformations – Cohort design

1.10.4. Antipsychotics: Neonatal and Obstetric Complications

Any antipsychotic - Neonatal and obstetric complications-Gestational diabetes - Cohort design

Any antipsychotic - Neonatal and obstetric complications-Small for gestational age - Cohort design

Any antipsychotic – Neonatal and obstetric complications-Large for gestational age – Cohort design

Any antipsychotic – Neonatal and obstetric complications-LBW (<2500g) – Cohort design

Any antipsychotic – Neonatal and obstetric complications-birth-weight – Cohort design

Any antipsychotic - Neonatal and obstetric complications-birth-weight - Case-control design

Any antipsychotic – Neonatal and obstetric complications-preterm delivery – Cohort design

Any antipsychotic – Neonatal and obstetric complications-Miscarriage Cohort design

Any antipsychotic – Neonatal and obstetric complications-still birth – Cohort design

Any antipsychotic - Neonatal and obstetric complications-Caesarean delivery - Cohort design

Any antipsychotic - Neonatal and obstetric complications-Gestational age at delivery - Cohort design

1.10.5. Antipsychotics: Neurodevelopmental outcomes

Any antipsychotic - Neurodevelopmental outcome - Mean score on the Infant Neurological Battery (at 6 months) - cohort design

Any antipsychotic - Neurodevelopmental outcomes-Delayed development - Bayley scales of infant development <85 - Cohort design

Any antipsychotic - Neurodevelopmental outcomes-Score on Bayley scales of infant development - Cohort design

1.10.6. Anticonvulsants: Teratogenic harms

Carbamazepine - Teratogenic harms - Major congenital malformations- cohort design

Lamotrigine - Teratogenic harms - Major congenital malformations-cohort design

Valproate – Teratogenic harms – Major congenital malformations-cohort design

Valproate - Teratogenic harms - Major congenital malformations - case control design

Carbamazepine – Teratogenic harms – Congenital malformations-cohort design

Valproate - Teratogenic harms - Congenital malformations-cohort design

Anticonvulsants – Teratogenic harms – neural tube defects-cohort design

Carbamazepine - Teratogenic harms - cleft lip/palate - cohort design

Lamotrigine – Teratogenic harms – cleft lip/palate – cohort design

Valproate – Teratogenic harms – cleft lip/palate – cohort design

1.10.7. Anticonvulsants: Neonatal and Obstetric harms

Carbamazepine - Neonatal and obstetric complications - admission to neonatal care - cohort design

Lamotrigine - Neonatal and obstetric complications - admission to neonatal care - cohort design

Valproate – Neonatal and obstetric complications – admission to neonatal care – cohort design

Carbamazepine – Neonatal and obstetric complications – stillbirth/perinatal death – cohort design

Lamotrigine - Neonatal and obstetric complications - stillbirth/perinatal death - cohort design

Valproate - Neonatal and obstetric complications - stillbirth/perinatal death - cohort design

Carbamazepine – Neonatal and obstetric complications – preterm birth – cohort design

Lamotrigine – Neonatal and obstetric complications – preterm birth – cohort design

Valproate - Neonatal and obstetric complications - preterm birth - cohort design

Carbamazepine - Neonatal and obstetric complications - birth weight - cohort design

Valproate – Neonatal and obstetric complications – birth weight – cohort design

1.10.8. Anticonvulsants: Neurodevelopmental outcomes

Carbamazepine - Neurodevelopmental outcomes - Full scale IQ - cohort design

Lamotrigine - Neurodevelopmental outcomes - Full scale IQ - cohort design

Valproate - Neurodevelopmental outcomes - Full scale IQ - cohort design

Carbamazepine – Neurodevelopmental outcomes – Verbal IQ – cohort design

Lamotrigine - Neurodevelopmental outcomes - Verbal IQ - cohort design

Valproate - Neurodevelopmental outcomes - Verbal IQ - cohort design

Carbamazepine - Neurodevelopmental outcomes - Performance IQ - cohort design

Lamotrigine - Neurodevelopmental outcomes - Performance IQ - cohort design

Valproate – Neurodevelopmental outcomes – Performance IQ – cohort design

Carbamazepine - Neurodevelopmental outcomes - Autism checklist score - cohort design

Lamotrigine - Neurodevelopmental outcomes - Autism checklist score - cohort design

Valproate – Neurodevelopmental outcomes – Autism checklist score – cohort design

Carbamazepine – Neurodevelopmental outcomes – Autism spectrum disorder – cohort design

Lamotrigine - Neurodevelopmental outcomes - Autism spectrum disorder - cohort design

Valproate - Neurodevelopmental outcomes - Autism spectrum disorder - cohort design

1.10.9. Lithium: Teratogenic harms

Lithium - Teratogenic harms - Congenital malformations - cohort design

Lithium - Teratogenic harms - Congenital malformations - case-control design

Lithium – Teratogenic harms – Heart defects – cohort design

Lithium – Teratogenic harms – Ebstein's anomaly – cohort design

1.10.10. Benzodiazepines: Teratogenic harms

Benzodiazepines - Teratogenic harms - congenital malformations - cohort design

Benzodiazepines - Teratogenic harms - congenital malformations - case- control design

Benzodiazepines - Teratogenic harms - major congenital malformations - cohort design

Benzodiazepines - Teratogenic harms - major congenital malformations - case-control design

Benzodiazepines – Teratogenic harms – cleft lip/palate – cohort design

Benzodiazepines - Teratogenic harms - cleft lip/palate - case-control design

Benzodiazepines - Teratogenic harms - cardiac abnormalities - cohort design

Benzodiazepines - Teratogenic harms - septal heart defects - cohort design

Benzodiazepines - Teratogenic harms - atrioventricular defects - cohort design

1.10.11. Benzodiazepines: Neonatal and Obstetric complications

Benzodiazepines – Neonatal and obstetric complications – gestational age at delivery – cohort design

Benzodiazepines – Neonatal and obstetric complications – birth weight – cohort design

Benzodiazepines - Neonatal and obstetric complications - caesarean delivery - cohort design

Benzodiazepines - Neonatal and obstetric complications - miscarriage - cohort design

Benzodiazepines - Neonatal and obstetric complications - instrumental delivery - cohort design

Benzodiazepines - Neonatal and obstetric complications - respiratory disorder - cohort design

1.10.12. Stimulants (methylphenidate): Teratogenic harms

Methylphenidate - Teratogenic harms - Major congenital malformations - cohort design

Methylphenidate - Teratogenic harms - Cardiac malformations - cohort design

1.11.1. Depression: Physical activity verses treatment as usual

Depression scores - Post-treatment - mean score at endpoint or first measurement – Available case analysis (no risk factors)

Depression symptomology - Post-treatment - number at short term follow-up – Available case analysis (no risk factors)

1.11.2. Depression: Physical activity combined with psychoeducation verses psychoeducation alone

Depression symptomology - Post-treatment - number at short term follow-up - ITT analysis (no risk factors)

Depression symptomology – Post-treatment – number at short term follow-up – ITT analysis (no risk factors)

1.11.3. Acupuncture versus placebo

Anxiety mean scores - Post-treatment – Available case analysis (identified risk factors)

Anxiety mean cortisol level - Post-treatment – Available case analysis (identified risk factors)

1.12.1. Response: Acupuncture versus massage

Non-response to treatment – Post-treatment – number at short term follow-up – (treatment)

1.12.2. Response: Depression specific acupuncture versus non-specific acupuncture

Non-response to treatment - Post-treatment - at endpoint or first measurement - (treatment)

1.12.3. Response: Bright light therapy versus placebo

Non-response - Post-treatment - at endpoint or first measurement - (treatment)

Non-remission - Post-treatment - at endpoint or first measurement - (treatment)

1.12.4. Depression: Physical activity versus treatment as usual

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement/Intermediate follow-up - (treatment) – Available case analysis

1.12.5. Depression: Physical activity versus mutual support

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement - (treatment) – Available case analysis

Depression symptoms - Mean depression scores Post-treatment - short-term follow-up - (treatment) – Available case analysis

1.12.6. Depression: Acupuncture versus massage

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement - (treatment) – Available case analysis

Depression symptoms - Mean depression scores Post-treatment - short-term follow-up - (treatment) – Available case analysis

Depression diagnosis – Above depression threshold – Post-treatment – short-term follow-up – (treatment) – Available case analysis

1.12.7. Depression: Depression-specific acupuncture versus non-depression specific acupuncture

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement - (treatment)

Depression symptoms – Mean depression scores Post-treatment – at short-term follow-up – (treatment)

Depression diagnosis – Above depression threshold – Post-treatment-at endpoint or first measurement – (treatment)

Depression diagnosis - Above depression threshold - Post-treatment - short-term follow-up - (treatment)

1.12.8. Depression: Electroacupuncture versus non-invasive sham acupuncture

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement - (treatment)

1.12.9. Depression: Massage combined with support versus support

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement - (treatment)

1.12.10. Depression: Massage versus support

Depression symptoms – Mean depression scores Post-treatment – at endpoint or first measurement – (treatment)

Depression symptoms - Mean depression scores Post-treatment - at long-term follow-up - (treatment)

1.12.11. Depression: Bright light therapy versus placebo

Depression symptoms - Mean depression scores Post-treatment - at endpoint or first measurement - (treatment)

1.12.12. Anxiety: Physical activity versus treatment as usual

Anxiety symptoms - Mean anxiety scores Post-treatment - at endpoint or first measurement -Available case analysis (treatment)

1.12.13. Anxiety: Electroacupuncture versus non-invasive sham acupuncture

Anxiety symptoms - Mean anxiety scores Post-treatment - at endpoint or first measurement - (treatment)

1.12.14. General mental health outcomes: Physical activity versus treatment as usual

Sleep disturbance symptoms - Mean scores - Post-treatment – Available case analysis (treatment)